Exyte, a global leader in high-tech facility design and engineering, has officially completed the integration of Pharmaplan, marking the full transition of the brand and unifying its biopharma engineering capabilities under a single organization. 

 

The move follows Exyte’s September 2024 acquisition of Pharmaplan, aimed at establishing a European champion and deepening partnerships with Europe’s fast-growing biotechnology and pharmaceutical sectors.

 

Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division.

 

“Bringing Pharmaplan fully into Exyte combines global delivery scale with five decades of life-sciences process and GMP expertise,” said Dr. Wolfgang Büchele, CEO of Exyte. “Our clients benefit from seamless EPC solutions, from concept design to compliant handover. We deliver with speed, precision, and reliability. Facilities are where pharmaceutical innovation becomes real.”

 

Since the acquisition, teams from both companies have collaborated to align systems, combine best practices, and ensure ongoing projects progressed without interruption. Client relationships have remained unaffected, and Exyte continues to deepen all partnerships previously managed by Pharmaplan.

 

Market and client feedback has been overwhelmingly positive, reflected in major wins, strong business acquisition, and record order intake projected for 2025. Joint projects have also expanded beyond Europe, including Southeast Asia, highlighting the combined reach and credibility of the integrated organization.

 

Following the integration, Exyte now offers Life Sciences services from over 40 locations across 12 European countries, positioning the company close to all key pharma and biotech markets. The company assumes full EPC/EPCM accountability—from feasibility studies, concept and basic design, detailed engineering, and construction management to commissioning, qualification, validation, and compliant handover.